The Anthem Biosciences IPO is off to a solid start, getting fully subscribed at 1.15 times by the second day of bidding on July 15, according to NSE data. This marks a strong response from investors, especially Non-Institutional Investors (NIIs) and Retail Individual Investors (RIIs).
The IPO, which opened on July 12 and closes on July 16, saw bids for 5.08 crore shares against 4.40 crore on offer as of 11 a.m. on Day 2.
NIIs Lead the Subscription Rally
What stood out in the subscription data was the robust demand from NIIs, whose portion was subscribed 2.82 times. Retail investors also participated actively, with RII quota reaching 89% subscription. Meanwhile, the Qualified Institutional Buyers (QIBs) category showed 38% subscription so far.
The numbers suggest increasing retail and NII confidence in the Bengaluru-based biotech company, which specialises in contract research and manufacturing.
Also Read: HCL Technologies Shares Slide 4% After Q1FY26 Miss
Listing, Allotment & Price Band
The Anthem Biosciences IPO allotment date is set for July 17, and the shares will be listed on both NSE and BSE on July 21.
IPO Size: ₹3,395 crore
Price Band: ₹540 to ₹570 per share
Anchor Investment Raised: ₹1,016 crore from institutional investors
What’s Next for Investors?
With strong participation already visible and a healthy grey market premium (GMP) buzz, all eyes are now on the allotment status and listing day performance.
If Day 2’s momentum continues, full subscription across all investor categories is likely by the close of the IPO. The biotech firm’s IPO has drawn attention for its growth potential in the pharma services sector.
